DGKK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21830991	1.00	1/20
SCHEMBL29654799	1.00	1/20
SCHEMBL23293507	0.87	1/20
SCHEMBL23293148	0.84	1/20
SCHEMBL23293265	0.84	1/20
SCHEMBL23293307	0.84	1/20
SCHEMBL23293196	0.83	1/20
SCHEMBL23293138	0.83	1/20
SCHEMBL30616370	0.83	1/20
SCHEMBL23293147	0.81	1/20
SCHEMBL23293186	0.81	1/20
SCHEMBL30422200	0.81	1/20
SCHEMBL23293506	0.81	1/20
SCHEMBL23293193	0.79	1/20
SCHEMBL23293351	0.79	1/20
SCHEMBL23293353	0.79	1/20
SCHEMBL30422106	0.79	1/20
SCHEMBL30616406	0.79	1/20
SCHEMBL23293169	0.78	1/20
SCHEMBL30616381	0.78	1/20

Clinical trials — most relevant to DGKK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
Biological Effects of Quercetin in COPD	PHASE1/PHASE2	UNKNOWN
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Tissue Lipids and Insulin Resistance	nan	WITHDRAWN
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome	nan	UNKNOWN
Study of Changes in Skeletal Muscle After Caloric Restriction	nan	ACTIVE_NOT_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Hypovitaminosis D and Metabolic Inflammatory Status in Patients With Obesity	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Oxidative Stress in Intestinal Metaplasia and Metabolic Syndrome	nan	UNKNOWN
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DGKK binder may also engage these)

Protein	Name	Similarity
Q9UPW5	—	0.977	Q9UPW5 →
Q641K1	—	0.977	Q641K1 →
Q9ESL4	—	0.976	Q9ESL4 →
F1R7R1	—	0.976	F1R7R1 →
P18514	—	0.974	P18514 →
Q6ZM86	—	0.974	Q6ZM86 →
MAP3K20	Mitogen-activated protein kinase kinase kinase 20	0.974	landscape →
Q5RED8	—	0.974	Q5RED8 →
Q62925	—	0.973	Q62925 →
P34908	—	0.973	P34908 →
O88974	—	0.973	O88974 →
Q9C5E5	—	0.973	Q9C5E5 →
Q62136	—	0.973	Q62136 →
Q8QFR2	—	0.972	Q8QFR2 →
Q8CGF6	—	0.972	Q8CGF6 →
Q9UPU7	—	0.972	Q9UPU7 →
E1C3P4	—	0.972	E1C3P4 →
E9PUQ8	—	0.972	E9PUQ8 →
Q9W5Z3	—	0.972	Q9W5Z3 →
Q8K2L8	—	0.972	Q8K2L8 →
Q7TPQ3	—	0.972	Q7TPQ3 →
MAP3K1	Mitogen-activated protein kinase kinase kinase 1	0.972	landscape →
Q69Z66	—	0.972	Q69Z66 →
Q80U62	—	0.972	Q80U62 →
Q640N2	—	0.971	Q640N2 →
P51126	—	0.971	P51126 →
A5PN09	—	0.971	A5PN09 →
Q9H8E8	—	0.971	Q9H8E8 →
P49140	—	0.971	P49140 →
Q6DD21	—	0.971	Q6DD21 →